TherapeutAix Roundup: 2024

As another year comes to a close, we reflect on 12 months filled with innovation and collaboration at TherapeutAix. From kickstarting the year with strategic planning in snowy Aachen to closing with a comprehensive review of IPF research, this year has been marked by exciting developments and impactful contributions to the life sciences sector. Here’s […]

Exploring the Potential of Inhalation Therapies for IPF: Lessons from Asthma

A few weeks ago, our updated review on the state of drug development in Idiopathic Pulmonary Fibrosis (IPF) was published in Drug Discovery Today. This update highlights the untapped potential of inhaled drug delivery in the treatment of IPF, a disease with poor prognosis and limited treatment options. It’s worth contrasting this therapeutic scenario with that […]

The Evolving Landscape of IPF Drug Discovery and Development

Idiopathic Pulmonary Fibrosis (IPF) remains one of the most challenging respiratory diseases to treat, characterized by progressive lung scarring and severely unpredictable disease progression. Despite high unmet clinical needs, the current standard of care—antifibrotic therapies nintedanib and pirfenidone—offers only modest benefits, with ongoing side effects that are a significant burden to patients. In our latest […]

ECM2024 meeting

ECM2024

In late June, Darcey Black (Director, Translational) attended and presented at the ECM2024 meeting in Copenhagen. This conference brought together speakers and experts from industry and academia to discuss the latest advances in fibrosis and related research.   ECM2024 covered a range of topics around the theme of the “ExtraCellular Matrix” (hence the title!), and […]

AI Target Identification: A novel approach to drive drug R&D in IPF?

  Within the realm of lung diseases, developing new drugs to treat Idiopathic Pulmonary Fibrosis (IPF) remains a formidable challenge. Characterized by progressive scarring of lung tissue, IPF significantly impairs breathing and has a median survival rate of just 2 to 3 years post-diagnosis. Current therapeutic options are limited, often providing only marginal relief while […]

First drug approval in NASH

NASH TherapeutAix

When we reviewed the R&D landscape in nonalcoholic steatohepatitis (NASH) in 2018, we highlighted 4 development programs that were in Phase 3 development and all targeting pivotal data readout, and a potential launch, between 2019 and 2021. However, obeticholic acid, elafibranor, cenicriviroc, and selonsertib all turned out to not confirm their initial positive data in […]

How rare diseases came to be defined: Rare Disease Day 2024

rare disease day 2024

Today is Rare Disease Day, an international awareness day that takes place annually on 28th February (or 29th on leap years like this one) – the rarest day of the year. In earlier blogs we looked at the relationship of rare diseases to common diseases, and how thinking about one can benefit thinking about the […]

Exciting news for inhaled lung fibrosis therapies

ipf inhaled therapies

Last year we made a series of posts highlighting the opportunities and challenges of developing inhaled therapies for idiopathic pulmonary fibrosis (IPF). In this blog, we provide an update on the most recent developments in inhaled IPF therapies. To recap the opportunities and challenges, the inhaled route offers the advantage of delivering a medicine directly […]

Did you know that TherapeutAix offer a project management service?

In this role, we provide oversight and co-ordinate activities of providers from within and outside our network to ensure timely and efficient provision of fit for purpose data. We believe that, by bringing the contributors together with regular meetings, we generate a value that is greater than the sum of the parts.   Three projects we […]

New Innovative Partnerships?

Pharma partnerships

Last year, Darcey Black, Director of Translational Science at TherapeutAix, together with colleagues, Gregor MacDonald from Lundbeck and Mo Alavijeh from Pharmidex organised a meeting for the Society of Medicines Research on “Innovative New Pharma and Biotech Partnerships: How is the landscape transforming?  The report of that successful meeting has just been published in Drugs […]

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.